Gout Treatment Prescribed by UK Doctors

Gout results from the deposition of monosodium urate (MSU) crystals in joints and periarticular tissues when serum urate exceeds its saturation point of approximately 360 micromol/L (6.0 mg/dL).

The UK prevalence has risen 64% over the past two decades, driven by increasing rates of obesity, metabolic syndrome, chronic kidney disease, and diuretic use.

Pathophysiology involves three stages. First, sustained hyperuricaemia (serum urate above 360 micromol/L) causes MSU crystal formation in joints and surrounding tissues.

Second, crystals trigger an intense inflammatory response mediated by NLRP3 inflammasome activation and IL-1-beta release from macrophages, producing the acute flare.

Third, chronic crystal deposition leads to tophaceous gout with joint erosion and renal urate nephropathy.

Clinical presentation of an acute flare is distinctive:

• Sudden onset of severe joint pain, typically nocturnal, reaching peak intensity within 12 hours
• First metatarsophalangeal (MTP) joint affected in 50-70% of initial presentations (podagra)
• The joint appears red, swollen, hot, and exquisitely tender — even bedsheet pressure is unbearable
• Systemic features: low-grade fever, malaise, elevated CRP
• Untreated, a flare resolves spontaneously in 7-14 days

Risk factors for hyperuricaemia and gout:

• Male sex (4:1 male predominance; women are relatively protected until menopause when oestrogen-mediated uricosuric effect declines)
• Obesity: BMI above 30 triples gout risk
• Alcohol: beer and spirits raise urate; wine in moderation has minimal effect
• Diet: purine-rich foods (organ meats, shellfish, red meat) increase urate production
• Medications: thiazide and loop diuretics, low-dose aspirin, ciclosporin reduce renal urate excretion
• Chronic kidney disease: eGFR below 60 doubles gout prevalence
• Metabolic syndrome: gout is independently associated with insulin resistance, hypertension, and dyslipidaemia

Joint aspiration with polarised light microscopy demonstrating negatively birefringent needle-shaped crystals is the gold-standard diagnostic test, though clinical diagnosis is reliable when the presentation is classic.

Prompt treatment of an acute gout flare aims to suppress inflammation and relieve pain as rapidly as possible.

NICE CKS and the British Society for Rheumatology (BSR) 2017 guidelines recommend three first-line options, chosen based on comorbidities and contraindications.

Colchicine is the preferred first-line agent when NSAIDs are contraindicated or not tolerated.

The current NICE-recommended regimen is 500 mcg two to four times daily until symptoms resolve or for a maximum of 3-4 days.

Higher doses (the historical "hourly until diarrhoea" regimen) are no longer recommended due to toxicity. The AGREE trial demonstrated that low-dose colchicine (1.2 mg followed by 0.

6 mg one hour later) was as effective as high-dose colchicine with significantly fewer GI side effects.

Colchicine works by inhibiting tubulin polymerisation in neutrophils, preventing the microtubule-dependent activation of the NLRP3 inflammasome.

It is most effective when started within 12 hours of flare onset.

NSAIDs provide rapid anti-inflammatory analgesia:

• Naproxen 500 mg twice daily or indomethacin 50 mg three times daily for 5-7 days
• Maximum dose for the first 48 hours, then step down
• Co-prescribe a PPI (omeprazole 20 mg) for GI protection
• Avoid in renal impairment (eGFR below 45), heart failure, and concurrent anticoagulation

Corticosteroids are used when both colchicine and NSAIDs are contraindicated (e.g., CKD plus heart failure):

• Prednisolone 30-35 mg daily for 5 days
• Intramuscular depot triamcinolone 40 mg for a single dose
• Intra-articular corticosteroid injection if a single large joint is affected and aspiration is feasible

Practical flare management tips:

• Apply ice packs (wrapped in cloth) to the affected joint for 20 minutes every 2-3 hours to reduce swelling
• Elevate the affected limb
• Do NOT start or adjust allopurinol during an acute flare — this can paradoxically worsen or prolong the episode
• If already taking allopurinol, continue at the same dose throughout the flare
• Hydrate well — dehydration increases serum urate concentration and prolongs crystal-mediated inflammation

Urate-lowering therapy (ULT) is the cornerstone of gout management, targeting the metabolic cause — hyperuricaemia — rather than simply treating the inflammatory consequence.

Despite this, ULT remains significantly underprescribed: only 27% of UK gout patients receive it, and fewer than half of those achieve target urate levels.

Allopurinol is the first-line ULT, recommended by NICE and the BSR.

It is a xanthine oxidase inhibitor that blocks the final step of uric acid synthesis, reducing production rather than increasing excretion.

Prescribing protocol:

• Start at 100 mg daily (50 mg if eGFR below 30 mL/min)
• Titrate upwards by 100 mg increments every 4 weeks, guided by serum urate measurement
• Target: serum urate below 300 micromol/L (below 360 micromol/L is the minimum; below 300 promotes crystal dissolution)
• Effective doses range from 100-900 mg daily; most patients require 300-600 mg
• The "start low, go slow" approach reduces the risk of allopurinol hypersensitivity syndrome

Febuxostat (80-120 mg daily) is a non-purine selective xanthine oxidase inhibitor used when allopurinol is not tolerated or contraindicated.

It is more potent: 80 mg febuxostat achieves target urate in 53% versus 21% for allopurinol 300 mg.

However, the CARES trial raised cardiovascular safety concerns (higher cardiovascular mortality, HR 1.34), so it is second-line and contraindicated in ischaemic heart disease.

Uricosuric agents (probenecid, sulfinpyrazone, lesinurad) increase renal urate excretion and are third-line options, typically used in combination with a xanthine oxidase inhibitor.

Prophylactic cover during ULT initiation is critical. Fluctuations in serum urate — even downward — can mobilise tissue crystal deposits and trigger flares. NICE and BSR recommend:

• Colchicine 500 mcg once or twice daily for 6 months from ULT initiation
• Alternative: low-dose NSAID (naproxen 250 mg daily) with PPI cover for 6 months
• This cover dramatically reduces early flares (from 30-40% to 5-10%) and improves ULT adherence

Indications for starting ULT:

• Two or more flares per year
• First flare with tophi, joint erosion on imaging, CKD stage 3+, or uric acid renal stones
• BSR 2017 also recommends offering ULT after the first flare if the patient is under 40 or has serum urate above 480 micromol/L

Dietary and lifestyle modification alone can reduce serum urate by 10-18%, which is insufficient for most patients to achieve target levels — hence the emphasis on pharmacotherapy.

Nevertheless, these measures reduce flare frequency, complement ULT, and improve the metabolic comorbidities that drive cardiovascular risk in gout patients.

Dietary urate management:

• Limit purine-rich foods: organ meats (liver, kidney), game, shellfish (mussels, scallops), and anchovies are the highest purine sources. Red meat and oily fish (sardines, mackerel) contribute moderately.
• Increase low-fat dairy intake: a meta-analysis showed that each daily serving of dairy reduces gout risk by 20%. The orotic acid and casein in milk promote renal urate excretion.
• Cherries and cherry extract: observational data (the Boston University online gout study) found that cherry consumption reduced gout flares by 35%. The mechanism involves anthocyanin-mediated anti-inflammatory effects and modest xanthine oxidase inhibition.
• Reduce fructose: sugar-sweetened beverages and high-fructose corn syrup increase hepatic urate production. Each daily sugary drink raises gout risk by 45%.
• Coffee: 4+ cups daily reduces gout risk by 40%, likely through xanthine-mediated uricosuric effects and anti-insulin resistance properties.

Alcohol management: Beer is the most goutigenic alcohol source — it contains both ethanol (which impairs renal urate excretion) and purine-rich brewer's yeast. Spirits carry moderate risk.

Wine in moderation (1-2 glasses) appears to have minimal effect on urate in most studies. During active gout or ULT titration, abstinence or strict limitation is advisable.

Weight management: Losing 5-10% of body weight reduces serum urate by 50-100 micromol/L in obese patients, which can be the difference between target achievement and failure on moderate-dose allopurinol.

Avoid crash dieting, which paradoxically raises urate through ketosis-mediated renal retention.

Hydration: Adequate fluid intake (2-2.5 litres daily, predominantly water) supports renal urate excretion.

Dehydration concentrates urate and increases crystallisation risk, which partly explains the nocturnal onset of flares (overnight fluid deficit).

Medication review: Diuretics (thiazides, furosemide) and low-dose aspirin (75-150 mg) raise serum urate by 30-50 micromol/L. Where possible, switch to urate-neutral antihypertensives.

Losartan and calcium channel blockers have mild uricosuric properties and are preferred in hypertensive gout patients.